Multiply Labs raises $75M Series B for robotic biomanufacturing

In short: On Oct 6, 2026 Multiply Labs announced a $75 million Series B led by Dr. Patrick Soon-Shiong with NantWorks, bringing total capital raised to over $100 million. New investors include AstraZeneca, Lingotto, Teradyne and Strange Ventures, alongside returning funds such as Casdin, Lux, Fifty Years, Ora Global and Founders Fund.

What the robots do

Multiply Labs builds robotic clusters that sit inside a pharma company's own facility and automate timed, repetitive biologics steps inside an enclosed, GMP-compliant system — without requiring a new plant or rewriting already-validated processes. The company says the platform can cut cost per dose by 74% and raise throughput by up to 100× versus manual manufacturing, and that clusters are owned and operated by the drugmaker, not run as outsourced CDMO capacity.

The roadmap started in cell and gene therapy and is expanding to antibodies, viral vectors and mRNA. A January 2026 collaboration with AstraZeneca evaluates GMP-ready systems for commercial-scale cell therapy; Multiply Labs also announced an NVIDIA Physical AI collaboration in January 2026.

Why it matters

AI is accelerating drug discovery faster than factories can make doses. Multiply Labs is betting that physical AI on the manufacturing floor — not more wet-lab headcount — closes that gap for therapies patients are waiting on.